{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:47:32Z","timestamp":1793296052526,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Postoperative nausea and vomiting (PONV) are significant issues in surgical patients, and additional treatment options are needed. Dopaminergic antiemetics have been popular for their efficacy, but their use has been limited by safety concerns, especially the potential for torsade de pointes arising from QT interval prolongation. Intravenous (IV) amisulpride, a dopamine D\n                      <jats:sub>2<\/jats:sub>\n                      and D\n                      <jats:sub>3<\/jats:sub>\n                      antagonist shown to be effective at preventing and treating PONV at doses of 5 and 10 mg, respectively, has a dose-dependent effect on QT but at 5 mg is not associated with clinically meaningful prolongation of the heart rate-corrected QT (QTc) interval. This study was designed to evaluate the QT effect of a 10-mg dose of amisulpride, alone and when simultaneously coadministered with ondansetron, an antiemetic of a different class, also known to prolong the QT interval.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>In this randomized, double-blind, placebo-controlled, 3-period, crossover study, healthy male and female volunteers 18\u201365 years of age received IV, in a random sequence: (1) amisulpride 10 mg given twice, 2 hours apart; (2) amisulpride 10 mg and ondansetron 4 mg, given simultaneously; and (3) placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Thirty subjects were enrolled, and 29 completed all 3 treatment periods. The largest mean placebo-corrected change-from-baseline QT interval corrected for heart rate using Fridericia\u2019s formula (QTcF) (\u0394\u0394QTcF) after the first and second amisulpride dose was 5.2 milliseconds (90% confidence interval [CI], 3.53\u20136.96 milliseconds) and 8.0 milliseconds (90% CI, 5.49\u201310.58 milliseconds), respectively. After coadministration of amisulpride and ondansetron, the largest mean \u0394\u0394QTcF was 7.3 milliseconds (90% CI, 5.48\u20139.16 milliseconds). The slope of the amisulpride concentration\u2013change-from-baseline QTcF (\u0394QTcF) relationship was 0.006 ms\/ng\/mL (90% CI, 0.0020\u20130.0098). No QTc outliers (absolute QTcF value &gt;480 milliseconds or increase from baseline &gt;30 milliseconds) were seen in any period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>A 10-mg dose of IV amisulpride, given alone or in combination with ondansetron, does not have a clinically significant effect on the QT interval.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000004538","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T12:29:54Z","timestamp":1578486594000},"page":"150-159","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting"],"prefix":"10.1213","volume":"132","author":[{"given":"Gabriel M.","family":"Fox","sequence":"first","affiliation":[{"name":"Department of Clinical Development, Acacia Pharma Ltd, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Albayaty","sequence":"additional","affiliation":[{"name":"Early Phase Clinical Unit, PAREXEL International, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna L.","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Acacia Pharma Ltd, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Xue","sequence":"additional","affiliation":[{"name":"eResearch Technologies Inc, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje","family":"Darpo","sequence":"additional","affiliation":[{"name":"eResearch Technologies Inc, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1213\/ANE.0000000000000002","article-title":"Consensus guidelines for the management of postoperative nausea and vomiting.","volume":"118","author":"Gan","year":"2014","journal-title":"Anesth Analg"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jclinane.2007.08.003","article-title":"The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia.","volume":"20","author":"Habib","year":"2008","journal-title":"J Clin Anesth"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/bja\/aet251","article-title":"I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial.","volume":"111","author":"Kranke","year":"2013","journal-title":"Br J Anaesth"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/ALN.0000000000001458","article-title":"Intravenous amisulpride for the prevention of postoperative nausea and vomiting: two concurrent, randomized, double-blind, placebo-controlled trials.","volume":"126","author":"Gan","year":"2017","journal-title":"Anesthesiology"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/ALN.0000000000002133","article-title":"Amisulpride prevents postoperative nausea and vomiting in patients at high risk: a randomized, double-blind, placebo-controlled trial.","volume":"128","author":"Kranke","year":"2018","journal-title":"Anesthesiology"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1213\/ANE.0000000000003733","article-title":"Randomized, double-blind, placebo-controlled study of intravenous amisulpride as treatment of established postoperative nausea and vomiting in patients who have had no prior prophylaxis.","volume":"128","author":"Candiotti","year":"2019","journal-title":"Anesth Analg"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/ALN.0000000000002509","article-title":"Amisulpride for the rescue treatment of postoperative nausea or vomiting in patients failing prophylaxis: a randomized, placebo-controlled phase III Trial.","volume":"130","author":"Habib","year":"2019","journal-title":"Anesthesiology"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","article-title":"The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance.","volume":"159","author":"Darpo","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bcp.13128","article-title":"Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects.","volume":"83","author":"T\u00e4ubel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R11-20250502","first-page":"401","article-title":"Improving the precision of QT measurements.","volume":"18","author":"Darpo","year":"2011","journal-title":"Cardiol J"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling.","volume":"45","author":"Garnett","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R14-20250502","first-page":"S65","article-title":"Simple, automatic noncompartmental analysis: The PKNCA R Package.","volume":"42","author":"Denney","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/jcph.322","article-title":"Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study.","volume":"54","author":"Zuo","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40264-015-0325-5","article-title":"Implications of the IQ-CSRC Prospective Study: time to revise ICH E14.","volume":"38","author":"Darpo","year":"2015","journal-title":"Drug Saf"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ALN.0b013e31817fd8c8","article-title":"Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.","volume":"109","author":"Charbit","year":"2008","journal-title":"Anesthesiology"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2253-6-6","article-title":"Anesthesiologists\u2019 practice patterns for treatment of postoperative nausea and vomiting in the ambulatory Post Anesthesia Care Unit.","volume":"6","author":"Macario","year":"2006","journal-title":"BMC Anesthesiol"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0952-8180(99)00067-7","article-title":"Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial.","volume":"11","author":"Kovac","year":"1999","journal-title":"J Clin Anesth"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:28:59Z","timestamp":1786112939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000004538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000004538","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,9]]}}}